Tests detecting biomarkers for screening of colorectal cancer: What is on the horizon?
| Autor: | Angaja, Phalguni, Helen, Seaman, Kristina, Routh, Stephen, Halloran, Sue, Simpson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
lcsh:R723-726
lcsh:Medical technology screening colorectal cancer 610 Medical sciences Medicine colorectal neoplasms Article cancer screening tests early diagnosis of cancer colorectal tumors lcsh:R855-855.5 ddc: 610 colorectal carcinoma cancer screening lcsh:Medical philosophy. Medical ethics early detection |
| Zdroj: | GMS Health Technology Assessment; VOL: 11; DOC01 /20150610/ GMS Health Technology Assessment, Vol 11, p Doc01 (2015) GMS Health Technology Assessment |
| ISSN: | 1861-8863 |
| Popis: | Aim: To identify new and emerging screening tests for colorectal cancer (CRC) that involves detection of various biomarkers like blood, DNA and RNA in samples of faeces, tissue or blood. Current practice: Screening for CRC can be done by bowel visualisation techniques and tests that measure biomarkers. The Bowel Cancer Screening Programme (BCSP) in England uses a guaiac faecal occult blood test. Methods: The strategy was to search available literature, identify developers and contact them for relevant information. Advice from experts was sought on potential utility and likely impact of identified technologies on the BCSP. Results: Ninety-three companies and five research groups were contacted. Sixty-nine relevant tests were identified. Detailed information was available for 48 tests, of these 73% were CE marked and the remainder were considered as emerging. Forty-nine tests use immunochemical methods to detect occult blood in faeces. Eight, four and two tests detect biomarkers in a sample of blood, or exfoliated cells either shed in faeces or collected from rectal mucosa respectively. Six tests were grouped as ‘other tests’. Most of the identified tests are performed manually and give qualitative detection of biomarkers. Conclusion: Variation in test performance and characteristics was observed amongst the 69 identified tests. Automated, quantitative FIT with a variable cut off are the preferred approach in the BSCP. However the units used to report FITs results do not enable comparison across products. Tests detecting biomarkers other than occult blood are more specific to neoplasms but have limited sensitivity due to the heterogeneity of cancer. Research is ongoing to identify an optimal panel of biomarkers, simplifying and automating the test, and reducing the cost. GMS Health Technology Assessment; 11:Doc01; ISSN 1861-8863 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|